Date: Mar. 24t	h, 2023	Youghny	Than
Your Name:	XXXX	lonegray	over !

Manuscript Title: Efficacy and safety of Lianhua Qingwen capsules combined with standard of care in the treatment of adult patients with mild to moderate COVID-19 (FLOSAN): protocol for a randomized, double-blind, international

multicenter clinical trial

Manuscript number (if known): JTD-23-281-R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
L	ALT SHARE	Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Shijiazhuang Yiling Pharmaceutical Co. Ltd	
-		Time frame: pa	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	

Consulting fees	XNone	
	0 1	
	XNone	
ectures, presentations, speakers bureaus, manuscript writing or educational events		
Payment for expert	XNone	
testimony		
Support for attending	XNone	
meetings and/or travel		
Patents planned, issued or	XNone	
pending		
Participation on a Data	_X_None	
Safety Monitoring Board or		
Advisory Board	Name of the Party	
	XNone	
	The state of the s	
	V None	
Stock of Stock options	X_None	
Receipt of equipment	X None	
	X_NONE	
writing, gifts or other services		
Other financial or non-	X None	
financial interests		
	Payment or honoraria for ectures, presentations, peakers bureaus, manuscript writing or educational events Payment for expert estimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other services Other financial or non-	Payment or honoraria for ectures, presentations, peakers bureaus, manuscript writing or educational events Payment for expert estimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other services Other financial or non- X_None

This trial was financially supported by Shijiazhuang Yiling Pharmaceutical Co. Ltd, providing funding and interventional drugs and is not involved in this trial, including the planning, execution, data management, statistical analysis, evaluation, or writing of the study.

Please place an "X" next to the following statement to indicate your agreement:

Date: Mar. 24th, 2023

Your Name: XXXX

Ruifeng ohen

Manuscript Title: Efficacy and safety of Lianhua Qingwen capsules combined with standard of care in the treatment of adult patients with mild to moderate COVID-19 (FLOSAN): protocol for a randomized, double-blind, international multicenter clinical trial

Manuscript number (if known): JTD-23-281-R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Shijiazhuang Yiling Pharmaceutical Co. Ltd	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	

4	Consulting fees	XNone	
5	Payment or honoraria for	X None	
5	lectures, presentations,	XNone	
	speakers bureaus,		
	manuscript writing or		
	educational events	V. Nana	
6	Payment for expert testimony	XNone	
	,		
7	Support for attending meetings and/or travel	XNone	
	,		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	X None	
10	in other board, society,	XNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Passint of aguinment	V None	
12	Receipt of equipment, materials, drugs, medical	X_None	
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		

This trial was financially supported by Shijiazhuang Yiling Pharmaceutical Co. Ltd, providing funding and interventional drugs and is not involved in this trial, including the planning, execution, data management, statistical analysis, evaluation, or writing of the study.

Please place an "X" next to the following statement to indicate your agreement:

Date: Mar. 24th, 2023
Your Name: Dingshou Zhong
Manuscript Title: Efficacy and safety of Lianhua Qingwen capsules combined with standard of care in the treatment of adult patients with mild to moderate COVID-19 (FLOSAN): protocol for a randomized, double-blind, international

multicenter clinical trial

Manuscript number (if known): JTD-23-281-R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Shijiazhuang Yiling Pharmaceutical Co. Ltd	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	

4	Consulting fees	XNone	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	X None	
O	testimony		
	testimon,		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Descipt of aguinment	V None	
12	Receipt of equipment, materials, drugs, medical	X_None	
	writing, gifts or other		
	services		
12	Other financial or non-	V None	
13	financial interests	XNone	
	manda micrests		

This trial was financially supported by Shijiazhuang Yiling Pharmaceutical Co. Ltd, providing funding and interventional drugs and is not involved in this trial, including the planning, execution, data management, statistical analysis, evaluation, or writing of the study.

Please place an "X" next to the following statement to indicate your agreement:

Date: Mar. 24th, 2023

2	Your Name: WWW VI Manuscript Title: Efficacy and safety of Lianhua Qingwen capsules combined with standard of care in the treatment of idult patients with mild to moderate COVID-19 (FLOSAN): protocol for a randomized, double-blind, international inulticenter clinical trial
	Manuscript number (if known): JTD-23-281-R1
r	the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are elated to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third arties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment or transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a elationship/activity/interest, it is preferable that you do so.
	the state of the state of the state of the surrent

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Shijiazhuang Yiling Pharmaceutical Co. Ltd	
		Time frame: pas	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	

4	Consideration	X None	
4	Consulting fees		
F	Devenue as homograpia for	X None	
5	Payment or honoraria for lectures, presentations,		
	speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	_X_None	
1000			
8	Patents planned, issued or	_X_None	
	pending		
9	Participation on a Data	X None	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		The same of the sa
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	_X_None	
NO THE			
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	X None	
	financial interests		
1989			Communication of the control of the
		The same of the sa	

This trial was financially supported by Shijiazhuang Yiling Pharmaceutical Co. Ltd, providing funding and interventional drugs and is not involved in this trial, including the planning, execution, data management, statistical analysis, evaluation, or writing of the study.

Please place an "X" next to the following statement to indicate your agreement:

Date: Mar. 24th,	2023	1
Your Name:	a Mr	M

Manuscript Time: Efficacy and safety of Lianhua Qingwen capsules combined with standard of care in the treatment of adult patients with mild to moderate COVID-19 (FLOSAN): protocol for a randomized, double-blind, international

multicenter clinical trial

Manuscript number (if known): JTD-23-281-R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Shijiazhuang Yiling Pharmaceutical Co. Ltd	
_		Time frame: pa	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	

Consulting fees	XNone	
	0 1	
	XNone	
ectures, presentations, speakers bureaus, manuscript writing or educational events		
Payment for expert	XNone	
testimony		
Support for attending	XNone	
meetings and/or travel		
Patents planned, issued or	XNone	
pending		
Participation on a Data	_X_None	
Safety Monitoring Board or		
Advisory Board	Name of the Party	
	XNone	
	The state of the s	
	V None	
Stock of Stock options	X_None	
Receipt of equipment	X None	
	X_NONE	
writing, gifts or other services		
Other financial or non-	X None	
financial interests		
	Payment or honoraria for ectures, presentations, peakers bureaus, manuscript writing or educational events Payment for expert estimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other services Other financial or non-	Payment or honoraria for ectures, presentations, peakers bureaus, manuscript writing or educational events Payment for expert estimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other services Other financial or non- X_None

This trial was financially supported by Shijiazhuang Yiling Pharmaceutical Co. Ltd, providing funding and interventional drugs and is not involved in this trial, including the planning, execution, data management, statistical analysis, evaluation, or writing of the study.

Please place an "X" next to the following statement to indicate your agreement:

Date: Mar. 24th, 2023	
Your Name:	tilleed

Your Name: 'The West Manuscript Title: Efficacy and safety of Lianhua Qingwen capsules combined with standard of care in the treatment of adult patients with mild to moderate COVID-19 (FLOSAN): protocol for a randomized, double-blind, international

multicenter clinical trial

Manuscript number (if known): JTD-23-281-R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Shijiazhuang Yiling Pharmaceutical Co. Ltd	
		Time frame: pas	t 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	X_None	
3	Royalties or licenses	XNone	

4	Consulting fees	X None	
Na I	Consulting rees		
5	Payment or honoraria for	X None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
6	educational events Payment for expert	X None	
0	testimony	A NOTICE	
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
MIG			
100			
8	Patents planned, issued or pending	X_None	
9	Participation on a Data Safety Monitoring Board or	X_None	
10	Advisory Board	V No.	
10	Leadership or fiduciary role in other board, society,	XNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
			THE CONTRACTOR OF THE CONTRACT
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other services		
/ 1		100	
13	Other financial or non-	XNone	
	financial interests		

This trial was financially supported by Shijiazhuang Yiling Pharmaceutical Co. Ltd, providing funding and interventional drugs and is not involved in this trial, including the planning, execution, data management, statistical analysis, evaluation, or writing of the study.

Please place an "X" next to the following statement to indicate your agreement:

Date: Mar. 24th, 2023 Your Name: M. Charlo

Manuscript Title: Efficacy and safety of Lianhua Qingwen capsules combined with standard of care in the treatment of adult patients with mild to moderate COVID-19 (FLOSAN): protocol for a randomized, double-blind, international

multicenter clinical trial

Manuscript number (if known): JTD-23-281-R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Shijiazhuang Yiling Pharmaceutical Co. Ltd	
BUE		Time frame: pa	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	

4	Consulting fees	XNone	
_		X None	7-1
5	Payment or honoraria for lectures, presentations,	X_None	
	speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	XNone	
	meetings and/or daver		
	X 5 7 3 3 3 7 7		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or Advisory Board	A PERSONAL PROPERTY.	[] 이번 1
10	Leadership or fiduciary role	XNone	
	in other board, society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	XNone	TO THE HAR THE SECTION OF THE PARTY OF THE P
12	Receipt of equipment, materials, drugs, medical writing, gifts or other	X_None	Control Derrace - 1010 Milester (1997) 11 To L. F. Harris C. F.
	services	8	
13	Other financial or non-	XNone	
	financial interests		

This trial was financially supported by Shijiazhuang Yiling Pharmaceutical Co. Ltd, providing funding and interventional drugs and is not involved in this trial, including the planning, execution, data management, statistical analysis, evaluation, or writing of the study.

Please place an "X" next to the following statement to indicate your agreement:

Date: Mar. 24th, 2023			
Your Name: Manuscript Title: Efficacy one safety of Lianhua Qingwen capsules combine			
Manuscript Title: Efficacy and safety of Lianhua Qingwen capsules combine	d with standard	of care in	the treatment of
adult patients with mild to moderate COVID-19 (FLOSAN): protocol for a rai	ndomized, doub	le-blind, ir	nternational
multicenter clinical trial			
Manuscript number (if known): JTD-23-281-R1			

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	vork
manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) Pharmaceutical Co. Ltd Pharmaceutical Co. Ltd	
Time frame: past 36 months	
2 Grants or contracts from any entity (if not indicated in item #1 above).	
3 Royalties or licensesX_None	

4	Consulting fees	X None	
Va I	Gonsam Brees		
5	Payment or honoraria for	X None	
	lectures, presentations,		
	speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	X_None	
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	X_None	
	pending		
9	Participation on a Data Safety Monitoring Board or	XNone	
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	X_None	
12	Receipt of equipment,	X_None	
	materials, drugs, medical writing, gifts or other services		
13	Other financial or non- financial interests	XNone	

This trial was financially supported by Shijiazhuang Yiling Pharmaceutical Co. Ltd, providing funding and interventional drugs and is not involved in this trial, including the planning, execution, data management, statistical analysis, evaluation, or writing of the study.

Please place an "X" next to the following statement to indicate your agreement:

Date: Mar. 24th, 2023

Your Name:

Manuscript Title: Efficacy and safety of Lianhua Qingwen capsules combined with standard of care in the treatment of adult patients with mild to moderate COVID-19 (FLOSAN): protocol for a randomized, double-blind, international multicenter clinical trial

Manuscript number (if known): JTD-23-281-R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Shijiazhuang Yiling Pharmaceutical Co. Ltd	
37		Time frame: pas	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	X_None	

4	Consulting fees	X None	
Va I	Gonsam Brees		
5	Payment or honoraria for	X None	
	lectures, presentations,		
	speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	X_None	
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	X_None	
	pending		
9	Participation on a Data Safety Monitoring Board or	XNone	
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	X_None	
12	Receipt of equipment,	X_None	
	materials, drugs, medical writing, gifts or other services		
13	Other financial or non- financial interests	XNone	

This trial was financially supported by Shijiazhuang Yiling Pharmaceutical Co. Ltd, providing funding and interventional drugs and is not involved in this trial, including the planning, execution, data management, statistical analysis, evaluation, or writing of the study.

Please place an "X" next to the following statement to indicate your agreement:

Date:	Mar.	24th.	2023
-------	------	-------	------

Your Name: Gordon G. Liu, Peking University Institute for Global Health and Development (

Manuscript Title: Efficacy and safety of Lianhua Qingwen capsules combined with standard of care in the treatment of adult patients with mild to moderate COVID-19 (FLOSAN): protocol for a randomized, double-blind, international

multicenter clinical trial

Manuscript number (if known): JTD-23-281-R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Shijiazhuang Yiling Pharmaceutical Co. Ltd	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	

4	Consulting fees	XNone	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert testimony	XNone	
	testimony		
7	Support for attending	XNone	
,	meetings and/or travel		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Descript of a main and and	V Mara	
12	Receipt of equipment, materials, drugs, medical	X_None	
	writing, gifts or other		
	services		
12	Other financial or non-	X None	
13	financial interests	^_None	
	illialiciai liiterests		

This trial was financially supported by Shijiazhuang Yiling Pharmaceutical Co. Ltd, providing funding and interventional drugs and is not involved in this trial, including the planning, execution, data management, statistical analysis, evaluation, or writing of the study.

Please place an "X" next to the following statement to indicate your agreement:

Date: Mar. 24th, 2023

Your Name: \(\text{WY WW W}\)
Manuscript Title: Efficacy and safety of Lianhua Qingwen capsules combined with standard of care in the treatment of

adult patients with mild to moderate COVID-19 (FLOSAN): protocol for a randomized, double-blind, international

multicenter clinical trial

Manuscript number (if known): JTD-23-281-R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Shijiazhuang Yiling Pharmaceutical Co. Ltd	
		Time frame: pas	t 26 months
		and the same of th	St 30 IIIOIILIIS
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4			

4	Consulting fees	X None	
4	consulting rees		
5	Payment or honoraria for	X None	
	lectures, presentations,		
	speakers bureaus,	RISH THE SECTION	
	manuscript writing or		
	educational events	V Name	
6	Payment for expert	XNone	
	testimony		
7	Support for attending	X None	
1	meetings and/or travel		
13 000	meetings array or mars		
Belle			
8	Patents planned, issued or	X_None	
	pending		
9	Participation on a Data	X None	
	Safety Monitoring Board or Advisory Board		
Ball			
10	Leadership or fiduciary role	XNone	
	in other board, society,	THE RESERVE OF THE PARTY OF THE	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical	X_None	
	writing, gifts or other		
	services		THE ROLL OF THE PARTY OF THE PA
12	Other financial or non-	V N	
13	financial interests	XNone	
100	inidicial interests		

This trial was financially supported by Shijiazhuang Yiling Pharmaceutical Co. Ltd, providing funding and interventional drugs and is not involved in this trial, including the planning, execution, data management, statistical analysis, evaluation, or writing of the study.

Please place an "X" next to the following statement to indicate your agreement:

Date: Mar. 24th, 2023 Your Name: Alam gav Wi

Manuscript Title: Efficacy and safety of Lianhua Qingwen capsules combined with standard of care in the treatment of adult patients with mild to moderate COVID-19 (FLOSAN): protocol for a randomized, double-blind, international

multicenter clinical trial

Manuscript number (if known): JTD-23-281-R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Shijiazhuang Yiling Pharmaceutical Co. Ltd	
		Time frame: pas	t 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	

4	Consulting fees	X_None	
		W Market III	
5	Payment or honoraria for	XNone	
	lectures, presentations, speakers bureaus, manuscript writing or educational events		
6	Payment for expert	XNone	
	testimony		
			AND STATE OF THE PROPERTY OF T
7	Support for attending	_X_None	
	meetings and/or travel		
1900			
8	Patents planned, issued or	XNone	
	pending		
			And the second s
9	Participation on a Data Safety Monitoring Board or	XNone	
45	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	THE RESIDENCE OF THE PARTY OF T
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services	a regulation of	
13	Other financial or non-	XNone	
1	financial interests		
			Company of the Compan

This trial was financially supported by Shijiazhuang Yiling Pharmaceutical Co. Ltd, providing funding and interventional drugs and is not involved in this trial, including the planning, execution, data management, statistical analysis, evaluation, or writing of the study.

Please place an "X" next to the following statement to indicate your agreement:

Date:	Map	. 24	ψ,	2023
	,	>	1	5

Your Name:

Manuscript Title: Efficacy and safety of Lianhua Qingwen capsules combined with standard of care in the treatment of adult patients with mild to moderate COVID-19 (FLOSAN): protocol for a randomized, double-blind, international multicenter clinical trial

Manuscript number (if known): JTD-23-281-R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initi	Specifications/Comments (e.g., if payments were made to you or to your institution) al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Shijiazhuang Yiling Pharmaceutical Co. Ltd	
2	Grants or contracts from any entity (if not indicated in item #1 above).	NATCM	

3	Royalties or licenses	_X_None	
		CALLED THE SHAPE	
4	Consulting food	X None	
4	Consulting fees	xNone	
			7
5	Payment or honoraria for	XNone	
	lectures, presentations,		
YES	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	X None	
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
Man .			
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	X_None	
V	Safety Monitoring Board or		
10	Advisory Board	X None	
10	Leadership or fiduciary role in other board, society,	xivone	
	committee or advocacy		7-
	group, paid or unpaid		
11	Stock or stock options	X_None	
12	Descript of annihilation	V Name	
12	Receipt of equipment, materials, drugs, medical	X_None	
	writing, gifts or other		
	services		A CONTRACTOR OF THE PARTY OF TH
13	Other financial or non-	X None	
	financial interests		
	White the second		

This trial was financially supported by Shijiazhuang Yiling Pharmaceutical Co. Ltd, providing funding and interventional drugs and is not involved in this trial, including the planning, execution, data management, statistical analysis, evaluation, or writing of the study. This work was also supported by National Administration of Traditional Chinese Medicine (NATCM)(grant number: ZYYCXTU-D-202206)

Please place an "X" next to the following statement to indicate your agreement:

Date: Mar. 24 th , 2023	\vee
Your Name: 2 day	ary

Manuscript Title: Efficacy and safety of Lianhua Qingwen capsules combined with standard of care in the treatment of adult patients with mild to moderate COVID-19 (FLOSAN): protocol for a randomized, double-blind, international multicenter clinical trial

Manuscript number (if known): JTD-23-281-R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Shijiazhuang Yiling Pharmaceutical Co. Ltd	
		Time frame: pas	t 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	NATCM	

3	Royalties or licenses	XNone	
Sur.		HE WAS TO BE THE STATE OF THE S	PER PER MANAGEMENT OF THE PERSON OF THE PERS
4	Consulting fees	XNone	
5	Payment or honoraria for	XNone	
- 0	lectures, presentations,	the state of the s	
M S	speakers bureaus,		
1525	manuscript writing or educational events		
6	Payment for expert	XNone	
١	testimony	XNone	
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
046			
8	Patents planned, issued or	XNone	
	pending		
0	Participation on a Data	X None	
9	Safety Monitoring Board or	XNone	
145100	Advisory Board		
10	Leadership or fiduciary role	X None	
10	in other board, society,		
	committee or advocacy		1.00
	group, paid or unpaid		
11	Stock or stock options	X None	
W. D			
12	Receipt of equipment,	X None	
	materials, drugs, medical		
	writing, gifts or other		- A
	services		
13	Other financial or non-	X None	
	financial interests		
	SETTING THE STATE OF	William William William	TO THE OWNER OF THE PERSON OF

This trial was financially supported by Shijiazhuang Yiling Pharmaceutical Co. Ltd, providing funding and interventional drugs and is not involved in this trial, including the planning, execution, data management, statistical analysis, evaluation, or writing of the study. This work was also supported by National Administration of Traditional Chinese Medicine (NATCM)(grant number: ZYYCXTU-D-202206)

Please place an "X" next to the following statement to indicate your agreement:

Date: Mar. 24 th , 2023	20 mm
Your Name:	COO WILL

Manuscript Title: Efficacy and safety of Lianhua Qingwen capsules combined with standard of care in the treatment of adult patients with mild to moderate OVID-19 (FLOSAN): protocol for a randomized, double-blind, international multicenter clinical trial

Manuscript number (if known): JTD-23-281-R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initi	Specifications/Comments (e.g., if payments were made to you or to your institution) al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Shijiazhuang Yiling Pharmaceutical Co. Ltd	
		Time frame: pas	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	NATCM	

3	Royalties or licenses	X_None	
			In contact the state of the second
4	Consulting fees	X None	Jam
1	Consulting rees	X_None	A 4 27
5	Payment or honoraria for	X_None	Christian Films Paris Care Contractor
12	lectures, presentations, speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	XNone	
	testimony		-
7	Support for attending	X None	
hor	meetings and/or travel		
10 m			
Harri			
8	Patents planned, issued or	X None	
8	pending	X_None	
9	Participation on a Data	_X_None	
1.3	Safety Monitoring Board or	Total Company	
10	Advisory Board Leadership or fiduciary role	X None	
10	in other board, society,	X_None	-
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	_X_Noñe	
Bi			
12	Receipt of equipment, materials, drugs, medical	X_None	
	writing, gifts or other services		in and the second secon
13	Other financial or non-	XNone	
	financial interests		Control of the contro
		The second of th	

This trial was financially supported by Shijiazhuang Yiling Pharmaceutical Co. Ltd, providing funding and interventional drugs and is not involved in this trial, including the planning, execution, data management, statistical analysis, evaluation, or writing of the study. This work was also supported by National Administration of Traditional Chinese Medicine (NATCM)(grant number: ZYYCXTU-D-202206)

Please place an "X" next to the following statement to indicate your agreement: